[1] |
Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet, 1964; 283, 702−3. |
[2] |
Gao Y, Tie YQ, Zhao LQ, et al. Rapid internal control reference recombinase-aided amplification assays for EBV and CMV detection. Biomed Environ Sci, 2021; 34, 650−5. |
[3] |
Styczynski J, van der Velden W, Fox CP, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica, 2016; 101, 803−11. doi: 10.3324/haematol.2016.144428 |
[4] |
Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol, 2001; 1, 75−82. doi: 10.1038/35095584 |
[5] |
Babcock GJ, Decker LL, Volk M, et al. EBV persistence in memory B cells in vivo. Immunity, 1998; 9, 395−404. doi: 10.1016/S1074-7613(00)80622-6 |
[6] |
Kasahara Y, Yachie A. Cell type specific infection of Epstein-Barr virus (EBV) in EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Crit Rev Oncol Hematol, 2002; 44, 283−94. doi: 10.1016/S1040-8428(02)00119-1 |
[7] |
Kimura Y, Takada T, Strasberg SM, et al. TG13 current terminology, etiology, and epidemiology of acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci, 2013; 20, 8−23. doi: 10.1007/s00534-012-0564-0 |
[8] |
Huo L, Jiang MY, Li Q, et al. Novel association of killer cell immunoglobulin-like receptor genes with EBV-infectious diseases in children. Biomed Environ Sci, 2015; 28, 303−7. |
[9] |
Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene, 2003; 22, 5108−21. doi: 10.1038/sj.onc.1206556 |
[10] |
Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer, 2004; 4, 757−68. doi: 10.1038/nrc1452 |
[11] |
Arai A. Advances in the study of chronic active Epstein-Barr virus infection: clinical features under the 2016 WHO classification and mechanisms of development. Front Pediatr, 2019; 7, 14. doi: 10.3389/fped.2019.00014 |
[12] |
Lindsay J, Yong MK, Greenwood M, et al. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation. Rev Med Virol, 2020; 30, e2108. |
[13] |
Jaiswal SR, Bhakuni P, Bhagwati G, et al. Alterations in NKG2A and NKG2C subsets of natural killer cells following Epstein-Barr virus reactivation in CTLA4Ig-based haploidentical transplantation is associated with increased chronic graft-versus-host disease. Transplantation, 2020; 104, e23−30. doi: 10.1097/TP.0000000000002941 |
[14] |
van Esser JWJ, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood, 2001; 98, 972−8. doi: 10.1182/blood.V98.4.972 |
[15] |
Xu LP, Zhang CL, Mo XD, et al. Epstein-Barr virus-related post-transplantation lymphoproliferative disorder after unmanipulated human leukocyte antigen haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes. Biol Blood Marrow Transplant, 2015; 21, 2185−91. doi: 10.1016/j.bbmt.2015.07.035 |
[16] |
van Esser JWJ, Niesters HGM, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood, 2002; 99, 4364−9. doi: 10.1182/blood.V99.12.4364 |
[17] |
Cohen J, Gandhi M, Naik P, et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol, 2005; 129, 229−39. doi: 10.1111/j.1365-2141.2005.05439.x |
[18] |
Arber DA, Kamel OW, van de Rijn M, et al. Frequent presence of the Epstein-Barr virus in inflammatory pseudotumor. Hum Pathol, 1995; 26, 1093−8. doi: 10.1016/0046-8177(95)90271-6 |
[19] |
Iezzoni JC, Gaffey MJ, Weiss LM. The role of Epstein-Barr virus in lymphoepithelioma-like carcinomas. Am J Clin Pathol, 1995; 103, 308−15. doi: 10.1093/ajcp/103.3.308 |
[20] |
Lee ES, Locker J, Nalesnik M, et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. New Engl J Med, 1995; 332, 19−25. doi: 10.1056/NEJM199501053320104 |
[21] |
Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol, 2007; 38, 1293−304. doi: 10.1016/j.humpath.2007.05.020 |
[22] |
Yamamoto N, Tokunaga M, Uemura Y, et al. Epstein-Barr virus and gastric remnant cancer. Cancer, 1994; 74, 805−9. doi: 10.1002/1097-0142(19940801)74:3<805::AID-CNCR2820740304>3.0.CO;2-L |
[23] |
Tabibzadeh A, Karbalaie Niya MH, Esghaei M, et al. Molecular epidemiology of Epstein-Barr virus (EBV) in patients with hematologic malignancies. Asian Pac J Cancer Prev, 2020; 21, 693−8. doi: 10.31557/APJCP.2020.21.3.693 |
[24] |
Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood, 1999; 94, 2208−16. |
[25] |
Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood, 2009; 113, 4992−5001. doi: 10.1182/blood-2008-09-178046 |
[26] |
Reddy N, Rezvani K, Barrett AJ, et al. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant, 2011; 17, 591−7. doi: 10.1016/j.bbmt.2010.08.007 |
[27] |
Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med, 2005; 56, 29−44. doi: 10.1146/annurev.med.56.082103.104727 |
[28] |
Peric Z, Cahu X, Chevallier P, et al. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. Leukemia, 2011; 25, 932−8. doi: 10.1038/leu.2011.26 |
[29] |
Riedel T, Rodriguez-Emmenegger C, de los Santos Pereira A, et al. Diagnosis of Epstein-Barr virus infection in clinical serum samples by an SPR biosensor assay. Biosens Bioelectron, 2014; 55, 278−84. doi: 10.1016/j.bios.2013.12.011 |
[30] |
Phaneuf CR, Oh K, Pak N, et al. Sensitive, microliter PCR with consensus degenerate primers for Epstein Barr virus amplification. Biomed Microdevices, 2013; 15, 221−31. doi: 10.1007/s10544-012-9720-1 |
[31] |
Hsieh HY, Chang R, Huang YY, et al. Continuous polymerase chain reaction microfluidics integrated with a gold-capped nanoslit sensing chip for Epstein-Barr virus detection. Biosens Bioelectron, 2022; 195, 113672. doi: 10.1016/j.bios.2021.113672 |
[32] |
Cui A, Wang SL, Zhang Q, et al. Development of a multiplex one-step real-time RT-PCR assay for the simultaneous detection of eight viruses associated with febrile rash illnesses. Biosaf Health, 2020; 2, 89−94. doi: 10.1016/j.bsheal.2020.04.003 |
[33] |
Li Q, Rane L, Poiret T, et al. Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning. Oncotarget, 2016; 7, 30230−40. doi: 10.18632/oncotarget.8803 |